A primary pathologic response to vascular injury is the proliferation and migration of vascular smooth muscle cells and the development of neointimal lesions. An increasing body of knowledge regarding the molecular and genetic basis of neointimal disease has created a unique opportunity for the treatment of this complex disorder. Gene therapy attempts to correct pathobiological processes by either inhibiting or correcting cellular functions at the level of gene expression. These endpoints are achieved by the delivery of either functional genes or oligonucleotides, capable of interfering with a cell's programmed machinery. Since the early 1990s, the evolution of this technology, along with an ever-expanding source of pathobiological information, has led to many novel approaches for the treatment of restenosis in arterial balloon injury as well as vein graft bypass failure. Using a variety of targets, inhibition of proliferation has predominantly been achieved through direct disruption of the cell cycle machinery. In addition, others have demonstrated successful inhibition by interfering with the signals for cellular proliferation or the enhancement of anti-proliferative stimuli. As this exciting therapeutic alternative evolves, improvements in safety, specificity and efficiency will enhance the likelihood of widespread clinical application.
Introduction
The prevalence of cardiovascular disease throughout the world, along with its associated morbidity, has prompted scientists to search for novel approaches towards the treatment of this complicated group of disorders. Recently, attention has become focused on the discovery and improved understanding of the genetic basis for cardiovascular pathobiology and the link between certain cardiovascular diseases and patterns of critical gene expression. Targeting of the pathogenic molecular machinery within cells and intact tissue has formed the theoretical basis for gene therapy as a means of treating complicated disease processes that have not been responsive to traditional pharmacologic therapies. 1, 2 The delivery and successful manipulation of gene expression in cells and tissues will be vital to the practical application of genetic therapies. These systems have included recombinant viral vectors that facilitate transfer of genetic information and oligonucleotides that can be used to alter native gene expression. 3 Vascular injury is known to result in smooth muscle cell proliferation and migration, leading to neointimal hyperplasia. Several groups have shown increased cytokine and adhesion molecule expression by neointimal cells, which contributes to the migration and accumulation of both vascular and inflammatory cells. 4, 5 A variety of critical factors involved in the molecular and biochemical pathways of vascular smooth muscle cell (VSMC) division and cell cycle progression have been identified. The role of these factors in the regulation of cellular proliferation is therefore an important determinant of the natural history of proliferative cardiovascular disorders, such as restenosis following balloon angioplasty. By targeting critical factors involved in driving cell cycle progression, the possibility of limiting or eliminating this pathogenic response exists. In this review, we will present the general strategies for gene therapy along with the current state of vector technology relevant to achieving effective gene transfer in cardiovascular tissue. Finally, we will detail the application of this exciting new technology towards the treatment of arterial restenosis and vein graft failure.
Strategies for gene therapy
Gene therapies can include any manipulation of gene activity, or gene 'expression,' that influences disease. This manipulation is generally achieved by introducing foreign DNA into cells via a process known as transduction or transfection. Gene therapy can involve either the delivery of whole, active genes (gene transfer), or the manipulation of native gene expression by the transfection of cells with short chains of nucleic acids known as oligonucleotides ( Figure 1) .
The gene transfer approach allows for the replacement of a missing gene product, or for the 'overexpression' of a native or foreign protein that can prevent or reverse a disease process. The transfer of a gene into a target cell leading to subsequent gene expression is known as transduction, and the new gene is referred to as the transgene. Gene replacement or augmentation involves the transfer of a gene that is either missing from a cell, present in a defective form or simply underexpressed relative to the level of protein expression desired by the clinician. The protein expressed may be active only intracellularly, in which case a very high gene transfer efficiency may be necessary to alter the overall function of an organ or tissue. Alternatively, proteins secreted by target cells may act on other cells in a paracrine or endocrine manner, in which case delivery to a small subpopulation may yield a sufficient therapeutic result.
In determining the efficiency of gene transfer into target cells, scientists have often relied on a class of genes known as reporter or marker genes. These genes encode proteins, Vascular Medicine 2000; 5: 103-114 such as a form of ␤-galactosidase found in Escherichia coli (known as lacZ or ␤-gal) or a small fluorescent molecule known as green fluorescent protein (GFP), which can be detected easily via histochemistry, fluorescent microscopy or other techniques that allow rapid identification and quantification of successful gene transfer.
In addition to effective gene delivery, many therapeutic settings will demand some degree of control over the duration, location and degree of transgene expression. To this end, researchers have developed first-generation gene promoter systems that allow the clinician to regulate the spatial or temporal pattern of gene expression. These systems include tissue-specific promoters that have been isolated from genetic sequences encoding proteins with natural restriction to the target tissue, such as the von Willebrand factor promoter in endothelial cells and the ␣-myosin heavy chain promoter in myocardium. Promoters have also been isolated that can either promote or inhibit downstream gene expression in the presence of a pharmacologic agent such as tetracycline or steroids. In addition, autoregulation of transgene expression may even be possible with the incorporation of promoters or enhancers that respond to specific physiologic conditions such as hypoxia or increased oxidative stress. [6] [7] [8] Gene blockade can be accomplished by the transfection of cells with short chains of DNA, known as oligonucleotides (ODN), which interfere with gene expression either at the level of RNA or protein. Although traditional phosphodiester ODN are susceptible to exo-and endonuclease digestion, ODN with phosphodiesterase-resistant modifications of the phosphate backbone, such as phosphoramidate and phosphorothioate ODN, can be used for more prolonged inhibition of gene expression. 9 In order to control for the potential non-specific effects of ODN transfection 10,11 on cell biology and protein expression, it is important that experiments are designed with adequate controls, including sense, mismatch and reverse antisense sequence ODN.
The antisense ODN approach attempts to alter cellular function by the inhibition of specific gene expression. Antisense ODN are generally 15-20 bases in length, and are designed to have a base sequence that is complementary to a segment of the target gene which confers specificity to a single site within the genome. 12 This complimentary sequence allows the ODN to bind specifically to the corresponding segment of messenger RNA (mRNA) that is transcribed from the gene during expression. This binding of ODN to mRNA prevents the translation of RNA into the protein product of the gene. Furthermore, the formation of mRNA-DNA hybrids via antisense binding, leads to degradation of the message by RNAse-H. 13, 14 Another form of ODN-based gene inhibition involves the blockade of gene regulatory proteins known as transcription factors. Transcription factors regulate gene expression by binding to chromosomal DNA at specific enhancer regions, and serve to either activate or suppress the transcription of its adjacent gene. Double-stranded ODN are designed to mimic the binding sites of these transcription factors and act as 'decoys,' binding up the available transcription factor and preventing the subsequent activation or suppression of target genes. 15 A third type of gene blockade is the use of 'ribozymes,' which are segments of RNA that can act like enzymes to destroy only specific sequences of target mRNA. Ribozymes contain both a catalytic region that can cleave other RNA molecules in a sequence-specific manner, and an adjacent sequence that confers the specificity of the target. Because the sequence recognition portion of the ribozymes is generally limited to approximately six bases, these gene inhibitory agents are generally more susceptible to non-specific interactions than their antisense counterparts. 16 
Gene therapy vector systems
Although many cells will naturally take up DNA from their extracellular environment in small amounts, this uptake is inefficient and generally unsuitable to achieve a physiologically significant influence on the genetic function of either healthy or diseased tissues. Clinical gene therapies will therefore depend on the development of vectors that enhance the efficiency of DNA transfer both in vitro and in vivo. The 'ideal' DNA delivery vector would be capable of safe and highly efficient delivery to all cell types, both proliferating and quiescent, with the opportunity to select either short-term or indefinite gene expression. This ideal vector would also have the flexibility to accommodate genes of all sizes, incorporate control of the temporal pattern and degree of gene expression, and to recognize specific cell types for tailored delivery or expression. While progress is being made on each of these fronts individually, researchers remain far from possessing a single vector with all of these characteristics. Instead, a spectrum of vectors has evolved, each of which may find a niche in different early clinical gene therapy strategies.
Viruses are the most common vehicles for exogenous gene delivery into mammalian cells. Although they take on many distinct forms, all viruses consist of a genetic nucleic acid code encapsulated in a machinery that facilitates gene transfer and, in many cases, gene expression. Recombinant DNA technology has allowed scientists to alter the genetic material contained within viral particles, both to include target genes of interest and to remove viral genes toxic to the host tissue.
Recombinant viral particles employed as gene transfer vectors are distinguished from their naturally occurring derivative viruses by their inability to replicate. This is achieved by deleting structural and functional genes from the native viral genome that, in the normal virus life cycle, provide the blueprint for the new virus production in infected host cells. Instead, these endogenous viral genes are replaced by the gene chosen for transfer, coupled to necessary regulatory elements using recombinant technology. In order to 'package' these vectors into particles, cell lines are engineered to provide the missing viral proteins separately. The final vector particle is assembled to include the transgene construct in the genetic information, capable of infection of suitable target cells, without the complete life cycle of viral replication.
Although viral vectors represent nature's solution to the problem of efficient gene transfer, man's attempt to harness these resources has also been confounded by the biological barriers that have evolved to protect cells and organisms from viral infection. Immunologic responses not only limit the efficacy of viral gene transfer, particularly when repeat administrations are considered, but the inflammatory response to viral antigens, even those associated with replication-deficient vectors, may impede or negate the therapeutic benefits of expression of the transferred gene. 17 Furthermore, engineering of viral genomes does not always preclude residual cytotoxicity in infected cells, and the possibility for regression to replication proficiency or for further mutation and recombination with other virulent viruses in the environment pose biologic hazards that are difficult to quantitate or predict.
Scientists have therefore continued to explore non-viral avenues for achieving efficient DNA delivery. One advantage of non-viral delivery systems is that they can be used not only for gene transfer but also for the delivery of ODN and protein-nucleic acid complexes that can be used for alternative forms of genetic manipulation. Whereas transduction refers generally to the delivery of an intact gene to a target cell and infection is used to describe the process of viral gene delivery, transfection is a term used to describe non-viral (i.e. physical/chemical) delivery of genes or ODN. A brief description of DNA delivery vectors that have been exploited in the cardiovascular system follows ( Table 1) .
Adenoviral vectors
Recombinant adenoviruses have become the most widely used viral vectors for experimental in vivo gene transfer, and have been used extensively in animal models of cardiovascular disease. 18 Adenoviruses can infect non-dividing cells and do not integrate into the host genome. These vectors can therefore achieve relatively efficient gene transfer in quiescent vascular tissue, but transgenes are generally lost when cells are stimulated into rounds of cell division. Expression of DNA in a non-chromosomal, or episomal state, also appears to be less stable, and adenoviral transduction has proven to be transient in cells, even in the absence of replication. Most experimental adenoviral vectors have undergone deletion of the viral genes known as E1a and E1b, genes that play a critical role in the adenovi- ral replication cycle, in order to render the vectors replication-deficient. The E3 region has also been deleted, providing enough space in the recombinant genome for inserting DNA of up to 7.5 kb. Researchers are currently exploring removal of nearly all adenoviral genes, both to reduce the immunogenicity of the vector and to increase the size of possible transgene insertions.
Many scientists have concluded that the immune response to adenoviral antigens represents the greatest limitation to their use in gene therapy. Conventional vectors have generally achieved gene expression for only 1-2 weeks after infection. It is not certain to what extent the immune destruction of infected cells contributes to the termination of transgene expression given that the suppression of episomal transgene promoters appears to occur as well. However, longer expression has been documented after injection of tissues in immune-deficient mice. 19 The adenoviral vector has been postulated to provide an adjuvant effect that amplifies the immune response to either viral or transgene product antigens. 19 In the vasculature, physical barriers such as the internal elastic lamina apparently limit adenoviral infection to the endothelium, with significant gene transfer to the media and adventitia only occurring after injury has disrupted the vessel architecture. 20 Although gene delivery to 30-60% of cells after balloon injury has been reported with adenoviral vectors carrying reporter genes, the fact that atherosclerotic disease has also been found to limit the efficiency of adenoviral transduction may pose a significant problem for the treatment of human disease. 21
Retroviral vectors
Retroviruses encode an RNA-dependent DNA-polymerase, known as reverse transcriptase, that initiates the generation of the transcriptionally active double-stranded DNA from the viral RNA genome. Traditional retroviral vectors are based on the recombinant Malony murine leukemia virus (MMLV), which randomly integrates itself into the host cell genome. In order for this integration to take place, the infected cell must undergo cell division within a short time after infection, thus limiting the delivery of their DNA to replicating cells. Once viral gene integration has taken place, this exogenous genetic material continues to be passed on to subsequent generations of progeny cells, creating the possibility for stable gene expression. Recombinant, replication-deficient retroviruses have been used extensively for gene transfer in cultured vascular cells, where cell proliferation can be manipulated easily. Their use in vivo has been more limited owing to low transduction efficiencies, particularly in the cardiovascular system where most cells remain quiescent. Nabel and colleagues 22 first demonstrated the feasibility of transducing blood vessels with foreign DNA in vivo by infecting porcine iliofemoral arteries with a recombinant retroviral vector containing the ␤-galactosidase gene. Several cell types in the vessel wall were transduced, including endothelial and vascular smooth muscle cells (VSMC). Recent improvements in packaging systems (particularly the development of 'pseudotyped' retroviral vectors that incorporate the vesicular stomatitis virus G-protein) have improved the stability of retroviral particles and facilitated their use in a wider spectrum of target cells. 23 Contrary to the dogma of MMLV biology, where cellular replication is necessary for incorporation into the genome, lentivirus, another class of retroviruses, has been shown to integrate effectively into the host genome in the absence of replication. 24 This is an attractive alternative for gene transfer into cardiovascular tissue and remains to be investigated.
The random integration of recombinant retroviruses into chromosomal DNA involves a potential hazard of oncogene activation and neoplastic cell growth. While the risk may be exceedingly low, safety monitoring will be an important aspect of clinical trials using viral vectors. Given that lentiviruses are members of the HIV family, concerns over mutation into its pathogenic phenotype pose significant concerns regarding the future use of these vectors in clinical trials.
Adeno-associated viral vectors
Adeno-associated virus (AAV) is a dependent human parvovirus that is not able to replicate unless a helper virus, such as adenovirus or herpes virus, is present in the same cell. AAV has not been linked to human disease. It can infect a wide range of target cells, and can establish a latent infection by integration into the genome of the cell, thereby yielding stable gene transfer as in the case of retroviral vectors. Although AAV vectors transduce replicating cells at a more rapid rate, they possess the ability to infect nonreplicating cells both in vitro and in vivo. AAV is limited by its small size (transgenes cannot be longer than about 4 kb), and the need to eliminate helper viruses from viral preparations. Early applications of AAV vectors to human gene therapy have included phenotypic correction of Fanconi anemia 25 expression of the cystic fibrosis transmembrane conductance regulator in airway epithelial cells. 26 The efficiency of AAV-mediated gene transfer to vascular cells, and the potential use of AAV vectors for in vivo vascular gene therapy, remains to be determined. A number of groups, however, have reported the successful transduction of myocardial cells after direct injection, ex-vivo perfusion or coronary infusion of AAV suspensions into the heart tissue, and these infections have yielded relatively stable expression for more than 60 days. 27, 28 It has not yet been clearly established whether long-term recombinant AAV transgenic expression is associated with genomic integration as is the wild-type AAV infection. In general, AAV transgene expression in vivo does not occur at significant levels during the first 2-4 weeks after infection, although the reason for this delay remains speculative.
in hematopoietic cells and stable in vivo

Lipid-mediated gene transfer
Numerous non-viral methods are available for the delivery of DNA into cells in vitro, including calcium phosphate, electroporation and particle bombardment. The development of similarly effective non-viral methods of in vivo transfection, however, has posed a significant challenge to cardiovascular and other clinical researchers who hope to avoid cumbersome and invasive steps of harvesting and culturing tissues or cells from the patient. The encapsulation of DNA in artificial lipid membranes (liposomes) can facilitate its uptake and cellular transport. The primary advantages of lipid-based gene transfer methods are the ease of preparation and flexibility in substituting different transgene constructs in comparison with the relatively complex process of producing recombinant viral vectors. Cationic liposomes have been used extensively during the last 5 years for cellular delivery of plasmid DNA and antisense oligonucleotides.
A wide variety of cationic lipid preparations are currently available for DNA transfer both in vitro and in vivo. Early clinical trials with cationic-DNA complexes have focused primarily on direct injection into malignant tumors, such as metastatic melanoma, to induce a heightened anti-tumor immunologic response. 29 In addition to cationic lipids, other substances, such as lipopolyamines and cationic polypeptides, are now being investigated as potential vehicles for enhanced DNA delivery both for gene transfer and gene blockade strategies. 30
Fusigenic-liposome-mediated gene transfer (HVJliposomes)
This method utilizes a combination of fusigenic proteins of the Sendai virus (Hemagglutinating Virus of Japan; HVJ) in conjunction with neutral liposomes. 31 HVJ is an RNA virus and belongs to the paramyxovirus family, which has HN and F glycoproteins on its envelope. HN binds with glycol-type sialic acid groups that act as receptors on the cell surface, and F protein can interact directly with a cellular lipid bilayer and induce fusion. HVJ-liposomes consist of neutral liposomes complexed with the UV-light-inactivated HVJ virus. Fusion of HVJ-liposome complexes with the cell membrane results in the release of DNA directly into the cytosol. 32 In addition to enhancing fusion of the HVJ-liposome complex with cell membranes, the viral coat proteins appear to influence the intracellular fate of DNA delivered by this fusion. 33 HVJ-liposome methods have been successfully employed for gene transfer in vivo to many tissues including liver, kidney, and the vascular wall. A major limitation to current HVJ-liposome techniques is the need to undertake a multistep liposome preparation procedure immediately prior to use and the poor long-term stability of the complexes.
Pressure-mediated gene transfer
The delivery of genes to tissue without the need for viral or liposomal enhancement reduces the potential risks and side-effects that may limit the translation of gene transfer technology to wide-scale clinical applications. Recent reports have demonstrated that application of a controlled pressurized environment to cardiovascular tissue in a nondistending manner enhances both ODN and plasmid uptake and nuclear localization. 34, 35 Using this technique, delivery of ODN to venous and myocardial tissue resulted in a transfection efficiency of 90% (Figure 2 , see p. 104) and 50%, respectively. While tissue distension has been shown to lead to significant cellular injury, the application of nondistending pressure has not been found to have any adverse effects. The usefulness of this method for the delivery of therapeutic genes has been demonstrated in ex vivo gene delivery to both experimental and human vein grafts, and in heart transplantation models. 36, 37 Other in vivo gene transfer methods Plasmids are circular chains of DNA that were originally discovered as a natural means of gene transfer between bacteria. Naked plasmids can also be used to transfer DNA into mammalian cells. The direct injection of plasmid DNA into tissues in vivo can result in transgene expression. Plasmid uptake and expression, however, has generally been achieved at reasonable levels only in skeletal and myocardial muscle. 38 The uptake of naked ODN is also inefficient after either intravascular administration or direct injection. Various catheters that have been designed to enhance local drug delivery to isolated segments of target vessels have been proposed as vehicles for local vascular gene therapy.
Gene therapy for restenosis
The durability of percutaneous angioplasty and venous bypass grafting used to treat atherosclerotic occlusive vascular disease has been plagued and severely limited by restenosis and graft failure, respectively. In the case of balloon angioplasty, restenosis occurs in approximately 30-40% of treated coronary lesions and 30-50% of superficial femoral artery lesions within the first year, 39 while vein graft failure rates remain at 30-50% over a 5-10-year period. 40 Although intravascular stents may reduce the restenosis rates after angioplasty, the incidence remains high and long-term data are quite limited. Despite impressive technological advances in the development of minimally invasive and endovascular approaches to treat arterial occlusions, the full benefit of these gains awaits the solution of this fundamental biologic problem.
Restenosis is comprised of a contraction and fibrosis of the vessel wall known as remodeling. Although it is thought that remodeling may account for the majority of late lumen loss after balloon dilation of atherosclerotic vessels and Vascular Medicine 2000; 5: 103-114 vein grafting, an active growth of a fibrocellular lesion composed primarily of VSMC and extracellular matrix is known to be the primary pathologic response. The local nature of this phenomenon makes it an attractive target for gene therapy given that the tissue reaction which develops is directly accessible by the intervention itself. Additionally, the limitations of conventional pharmacotherapies along with the relative frequency of this problem (and the associated economic burden it poses), invites the potential application of this novel therapeutic approach. The role for gene therapy in the prevention of restenosis and graft failure will depend on the identification of appropriate molecular targets, a suitable vector system for efficiently targeting vessel wall cells, and methods of achieving local delivery without producing undue damage or distal tissue ischemia. Whereas traditional pharmacologic regimens require chronic administration of the therapeutic agent, the appropriate genetic modification, performed locally at the time of angioplasty or bypass grafting, could induce a long-term benefit in patency by fundamentally redirecting the healing response at its roots.
A number of molecular species have been implicated in the stimulation of VSMC to initiate the intimal hyperplastic process, including platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF), transforming growth factor-beta (TGF-␤), and angiotensin II. 41, 42 In an effort to determine an effective therapeutic target along with the overlapping nature of these proliferative factors, researchers have looked towards the cell cycle machinery as the final common pathway of this pathobiologic response. VSMC proliferation depends on the increased expression of certain cell cycle regulatory proteins at critical points along the cell cycle, including proliferating cell nuclear antigen (PCNA), cell division cycle 2 (cdc2) kinase, the cyclins and cyclin dependent kinases (cdk) (Figure 3 ). It has been hypothesized that by blocking the gene expression or function of one or more of these proteins, one could prevent the progression of VSMC through the cell cycle and inhibit neointimal hyperplasia.
Antisense approach
Initial experiments in cell culture indicated that transfection of VSMC with antisense ODN directed against the translation initiation site of cell cycle regulatory genes, such as PCNA, could, in fact, partially inhibit cellular proliferation in response to serum stimulation. Arrest of the cell cycle via antisense blockade of either of two proto-oncogenes, cmyb or c-myc, has been found to inhibit neointimal hyperplasia in models of arterial balloon injury. 43, 44 although the specific antisense mechanism of the ODN used in these studies has subsequently been questioned. 11 Similar degrees of inhibition have also been reported with antisense-targeted inhibition of PCNA, cdk2 kinase, and cyclin G1, individually. [45] [46] [47] Using antisense ODN directed against both cdc2 kinase and PCNA, Morishita and colleagues augmented the in vitro inhibition of VSMC proliferation previously reported, and were able to demonstrate near complete inhibition of neointimal hyperplasia after carotid balloon injury, via HVJ-liposome-mediated transfection. 48 The ODN treatment was both locally selective and sequence-specific because neointimal inhibition was limited to the transfected segment of injured carotid; adjacent untransfected segments developed neointimal lesions simi- lar to untreated carotids and to vessels transfected with control ODN that were subjected to balloon injury. Although the cell cycle has been the predominant target of ODNdirected inhibition of VSMC proliferation, targeting of mitogenic factors, specifically bFGF, using antisense ODN has been shown to be effective in reducing neointimal hyperplasia in vivo as well. 49 In an alternative approach to combating neointimal hyperplasia, rather than directly inhibiting VSMC proliferation, Pollman and colleagues 50 stimulated the endogenous machinery for VSMC 'suicide' in a strategy designed to achieve regression of neointimal lesions. This involved treatment of balloon-injured carotid arteries in cholesterolfed rabbits with antisense ODN targeting a 'survival' gene known as Bcl-x, which helps protect cells from activation of programmed cell death, or apoptosis. By preventing the expression of this survival gene in neointimal cells, the cells were directed into a pro-apoptotic state, subsequently leading to regression of the lesion.
In contrast to arterial balloon injury, vein grafts are not subjected to a single injury at the time of operation, but rather, are exposed to chronic hemodynamic stimuli for remodeling. In addition, some adaptive remodeling and wall thickening is necessary to reduce high levels of tangential wall stress in these previously thin-walled, lowpressure conduits. 51 Despite these chronic stimuli, we determined that treatment of rabbit vein grafts with a single ex vivo, intra-operative combination of antisense ODN against PCNA and cdc2 kinase rendered the grafts resistant to neointimal hyperplasia for at least 6 months after surgery. Additionally, the antisense ODN-treated grafts exhibited the capacity for adaptive remodeling and wall stress stabilization via hypertrophy of the medial layer. Furthermore, these genetically engineered conduits proved resistant to diet-induced atherosclerotic changes (Figure 4) .
Vein graft endothelium is known to exhibit abnormalities similar to those associated with native arterial atherogenesis. We examined the influence of antisense ODN against PCNA and cdc2 kinase on vein graft endothelial cell function. 52 Endothelial cell nitric oxide synthase (ecNOS) activity was noted to be improved in treated grafts as opposed to the reduction in activity seen in untreated and control ODN-treated grafts. This preserved function correlated with an improvement in graft vasoactivity as well. Further stabilization of endothelial cell phenotype was noted by a reduction in vascular cell adhesion molecule 1 (VCAM-1) expression and reduced monocyte adhesion. Upregulation of VCAM-1 in activated endothelial cells is believed to enhance adhesion of circulating inflammatory cells and therefore reducing its expression can effectively limit attachment of these inflammatory cells. Preliminary data from our group indicates that stabilization of endothelial cell function is not the result of a direct cell cycle inhibitory effect on the healing endothelia, 53 but rather due to the inhibition of neointima formation and its associated pathogenic stimuli.
Decoy approach
The successful long-term modification of vascular cell biology through a single intervention in cell cycle regulatory gene expression led to the exploration of other, potentially more efficient approaches to genetic control of the cell cycle. The activity of a number of cell cycle regulatory genes is influenced by a family of transcription factors known as E2F. 54 In quiescent cells, E2F is bound to a complex of other proteins, including a protein known as the retinoblastoma gene product (Rb), which prevents its interaction with chromosomal DNA and its stimulation of gene activity. In proliferating cells, E2F is released, resulting in cell cycle gene activation. Genes known to be upregulated by E2F binding include both PCNA and cdc2 kinase, along with the proto-oncogenes c-myb and c-myc, all of which have been shown to play critical roles in VSMC proliferation and neointimal hyperplasia. A transcription factor decoy bearing the consensus binding sequence recognized by E2F can be employed as a means to inhibit cellular proliferation. Such cis element decoys bind to the free transcription factor and prevent its interaction with the promoter regions of target genes.
Preliminary in vitro studies demonstrated that treatment of VSMC with E2F decoy ODN, inhibited serum-stimulated upregulation of PCNA, cdc2 kinase and c-myc expression along with blockade of cellular proliferation. Furthermore, using HVJ-liposome, Morishita and colleagues were able to demonstrate the use of this strategy to prevent VSMC proliferation and neointimal hyperplasia after rat carotid balloon injury. 55 Once again, neointimal hyperplasia was noted to be inhibited at least 8 weeks after injury and transfection, further supporting the hypothesis that intervention in critical gene expression during early pathogenesis can yield long-term effects on vascular Vascular Medicine 2000; 5: 103-114 biology and remodeling. Treatment of vein grafts with the E2F decoy ODN yielded a similar efficacy as the arterial injury model, and was able to adapt appropriately to arterial conditions via hypertrophy of the medial layer. Furthermore, these genetically engineered conduits proved resistant to diet-induced graft atherosclerosis. 56 A single-center, prospective, randomized double-blind trial of human vein graft treatment with E2F decoy ODN has been initiated. 36 Efficient delivery of the ODN is accomplished within 15 minutes during the operation by exposing the vessel to ODN in physiologic solution and simultaneous application of a pressure of 300 mmHg to all sides of the vessel, avoiding any potential mechanical injury. Preliminary findings have indicated ODN delivery to more than 80% of graft cells, and effective blockade of target gene expression. Primary graft failure was defined as graft occlusion, graft revision, or evidence on ultrasonography of a stenosis of greater than 75% at 12 months after surgery in those patients who were not candidates for revision. Preliminary analysis of graft failure rates 1 year after grafting demonstrated a reduction of primary failure rates in those grafts receiving E2F decoy ODN. Although the efficacy of this approach requires further validation in a large-scale multi-center trial, this study demonstrates the safety, feasibility and successful application of gene therapy to the treatment of vein graft stenosis.
The use of a transcription factor decoy poses certain advantages over treatment with antisense ODN. The upregulation of multiple genes by a single transcription factor can be targeted simultaneously through transfection of a single decoy ODN. This obviates the need for transfection of two or more antisense ODN species into a single cell, and may therefore increase the efficiency of this approach to genetic manipulation. Finally, the same non-specific effects on cell biology and protein expression observed with single-stranded ODN have yet to be documented with the transfection of double-stranded ODN, rendering this approach potentially safer and more effective.
Gene transfer approach
As previously mentioned, gene transfer refers to the delivery of functional genes in an effort to replace those that are missing or defective, and for the overexpression of those that already exist. Viral and non-viral vector systems have been shown to deliver genes effectively into cells of the vessel wall in both carotid artery and vein grafts. 18, 22, [57] [58] [59] [60] The feasibility of functional gene delivery has generated several exciting approaches towards combating the pathobiology of vascular remodeling and stenosis. Endothelial dysfunction plays an important role in vascular proliferative disease. 61 Denudation of the endothelium during balloon angioplasty is therefore believed to contribute to the pathogenesis of restenosis. Endothelial loss results in vasomotor abnormalities and in increased adhesion of platelets and blood-borne inflammatory cells. These phenomena are in part related to the loss of nitric oxide (NO) generation by ecNOS. Endothelial cell production of NO has other important homeostatic effects on the vessel wall, 62 including inhibition of VSMC proliferation and migration, and moderation of superoxide radical generation and oxidative state. In vivo transfer of plasmid DNA coding for ecNOS has been investigated as a potential paracrine strategy to block neointimal disease. EcNOS cDNA driven by a ␤-actin promoter and CMV enhancer was transfected into the VSMC of rat carotid arteries after balloon injury. This model is known to have no significant regrowth of endothelial cells within 2-3 weeks after injury and is therefore capable of loss of endogenous ecNOS expression. Results revealed expression of the transgene in the vessel wall, along with improved vasomotor reactivity and a 70% inhibition of neointima formation ( Figure 5 ). 57 These findings reflect the significant role a single gene product can play in the context of a complex disease process such as neointimal hyperplasia, and demonstrated the feasibility of targeting a physiologically important gene for overexpression as a therapeutic strategy in cardiovascular disease. Although expression of the transgene is limited, this study demonstrates that transient overexpression of a critical gene product during certain phases of proliferative disease can redirect long-term vascular remodeling.
Cell cycle inhibition has also been demonstrated via overexpression of mutant proteins or natural inhibitors of the cell cycle. Localized arterial infection with a replication-deficient adenovirus encoding a non-phosphorylatable, constitutively active form of Rb at the time of balloon angioplasty significantly reduced smooth muscle cell proliferation and neointima formation in both rat carotid and porcine femoral artery models of restenosis. 63 Similar results were also obtained via overexpression of the cyclindependent kinase inhibitor p21, which prevents hyperphos-Vascular Medicine 2000; 5: 103-114 phorylation of Rb, and of the Rb gene family member, RB2/p130, which blocks the release of E2F. In separate reports, adenovirus-mediated overexpression of these genes in a rat balloon injury model resulted in reduced VSMC proliferation and neointimal hyperplasia. 64, 65 In addition to blockade of cell cycle gene expression, interruption of mitogenic signal transduction has also been achieved in experimental models. Heterotrimeric G proteins have been shown to be important for the transduction of mitogenic signals from membrane to nucleus in several cell types. Translocation of the ␤-adrenergic receptor kinase (␤ARK-1) is a critical step in this process of signal transduction. Using a replication-deficient adenovirus encoding a 194 amino acid portion of the carboxy-terminal of ␤ARK-1 (␤ARKct), a known inhibitor of G protein transduction, Iaccarino and colleagues were able to demonstrate effective reduction of VSMC proliferation and neointimal formation in a rat carotid artery balloon injury model. 66 Ras proteins are key transducers of mitogenic signals in many cell types as well. The local delivery of DNA vectors expressing Ras dominant negative mutants, which interfere with Ras function, also reduced neointimal lesion formation in a rat model. 67 As previously described, the use of antisense ODN against Bcl-x led to neointimal cell death and lesion regression. Using an adenoviral vector, a 'suicide gene' such as the herpes simplex virus-TK (HSV-TK) was introduced into the VSMC of porcine arteries rendering the smooth muscle cells sensitive to the nucleoside analog gancyclovir given immediately after balloon injury. After one course of gancyclovir treatment, neointimal hyperplasia decreased by about 50%. 68 Another potentially relevant biologic strategy for the treatment of restenosis is re-endothelialization, which might be accelerated by local delivery of a pro-angiogenic factor (e.g. vascular endothelial cell growth factor, VEGF) at the angioplasty site. This is the basis for the only current US clinical trial of gene therapy for the prevention of restenosis in the peripheral circulation, in which the human VEGF gene is administered as a 'naked' circular DNA plasmid directly to the injured arterial wall on the surface of the angioplasty balloon. 69 The investigators hypothesize that the low efficiency of this delivery method is balanced by the high biologic potency of this secreted angiogenic cytokine, enabling a significant local biologic effect despite poor gene transfer.
An ex vivo gene transfer approach, involving implantation of genetically modified endothelial cells or VSMC at sites of arterial injury, has also been investigated. 70 Until recently, the need to harvest autologous donor tissue for target cells, coupled with the increased costs and complexity of tissue culture, have greatly dampened the enthusiasm for this strategy in favor of more direct methods. Recent reports, however, have demonstrated the feasibility of obtaining autologous immature endothelial cells from the peripheral circulation, which when placed in proper culture conditions, can be stimulated to differentiate into functional endothelial cells. 71 With the advent of this new technology, it remains clinically possible that implantation of these cells alone may confer beneficial properties to the healing arterial wall.
The feasibility of gene transfer in vein grafts has led to the investigation of potential therapeutic approaches of inhibiting neointimal hyperplasia. Using a replicationdeficient adenovirus expressing tissue inhibitor of metalloproteinase-2 (TIMP-2), George and colleagues were able to demonstrate a decrease in neointimal formation in a saphenous vein organ culture model. 72 In a rabbit vein graft model, intra-operative transfection of the senescent cellderived inhibitor (sdi-1) gene, a downstream mediator of the tumor suppresser gene p53, using the HVJ-liposome system, was found to partially inhibit neointima formation as well. 73 Finally, using a replication-deficient adenovirus, overexpression of a non-phosphorylatable, constitutively active Rb gene was also able to demonstrate a reduction in neointima formation. 74 
Summary
Advances in understanding the critical molecular events responsible for VSMC proliferation and neointimal hyperplasia have opened the doors for researchers to explore the novel and exciting approach of gene therapy towards limiting or preventing accelerated atherosclerosis and restenosis. The complex nature of this pathologic response to vascular injury has spawned several different treatment strategies. With the improvement of vector systems and an increase Vascular Medicine 2000; 5: 103-114 in gene transfer efficiency, along with a more detailed understanding of the biology of vascular remodeling, the potency of this therapeutic option will continue to expand. As the translation of this technology into a clinically viable alternative for patient care becomes more feasible, safety becomes an essential consideration. The use of viral vector systems pose several biologic hazards, ranging from viral cytotoxicity, to powerful immune reactions, to possible reversion or mutation back to a pathogenic viral phenotype, and finally to oncogene activation as a result of random integration into the genome. An ex vivo approach to gene transfer offers one alternative to limiting the potential systemic side effects of this form of treatment. The focus of improving existing techniques must consider not only the enhancement of efficiency and effect, but the reduction of potential risk to the patient. Continued progress on each of these fronts warrants an optimistic view that genetic approaches to controlling the vascular injury response may offer meaningful contributions in a clinical setting.
